Business Context and Reporting Period
Company: Zymeworks Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2025
Reporting Period: The filing announces financial results for the three months ended March 31, 2025.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release regarding Q1 2025 results but does not include the content of that commentary within the 8-K text.
Regulation FD: The Company discloses material information via SEC filings, press releases, conference calls, its website (www.zymeworks.com), investor relations site, and social media channels (X and LinkedIn).
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 8, 2025) for actual Q1 2025 financial figures.
- Verify the Company's cash position and burn rate in the full press release, as this 8-K does not state liquidity levels.
- Check the Company's investor relations website and social media channels for additional material disclosures as noted in Item 7.01.
- Confirm the trading symbol ZYME on The Nasdaq Stock Market LLC.